AVE.AU Avecho Biotechnology Ltd
- Market cap
- AUD 54.1M
- P/E
- -
- P/B
- 28.36x
- ROE
- -403.4%
- Dividend yield
- -
- Fundamental score
- 1.4/5
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is AVE.AU undervalued?
Graham numberThe Graham number of Avecho Biotechnology Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Avecho Biotechnology Ltd fundamental analysis
6 of 21 checks passedROE 0/2
Low return on equity (-403.4%), below 10%.
ROA 0/1
Return on assets (-91.5%) is below the industry median (-51.4%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 0/1
Last year's EPS growth (-35.2%) is below the industry median (-5.3%).
Revenue Growth 1/2
Revenue grew 3.1% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (11.9%), 40% or less.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Cash Runway 2/2
Cash covers 32.1 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 0/1
Price to book (28.4x) is above the industry median (4.4x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Avecho Biotechnology Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Avecho Biotechnology Ltd
Avecho Biotechnology Limited, a biotechnology company, develops and commercializes human and animal health products using its proprietary drug delivery system, tocopherol phosphate mixture (TPM) in Australia, Switzerland, France, and India. It operates through Production and Human Health segments. The company manufactures and sells TPM and Vital ET products for use in drug delivery and cosmetic formulations. Its human health portfolio covers delivery of pharmaceutical produc…
Full company profileAvecho Biotechnology Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Avecho Biotechnology Ltd annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.59M | 1.15M | 1.25M | 4.24M | 385K | 794K | 1.13M | 474K | 1.13M | 1.24M | 238K |
| Gross Profit | 1.26M | 1.06M | 699K | 4.02M | 241K | 508K | 793K | -43.8K | 672K | 751K | -43.2K |
| Operating Income | -9.29M | -9.06M | -5.33M | 1.57M | -3.39M | -4.55M | -3.06M | -4.59M | -4.96M | -6.00M | -13.0M |
| EBITDA | -9.56M | -9.04M | -4.60M | 1.20M | -2.45M | -2.98M | -2.11M | -3.24M | -2.92M | -5.87M | -12.8M |
| Net Income | -17.3M | -8.62M | -3.99M | 850K | -2.64M | -3.42M | -2.34M | -3.44M | -3.12M | -4.42M | -7.69M |
| EPS | -0.01 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Balance Sheet | |||||||||||
| Total Assets | 13.4M | 8.24M | 4.80M | 5.32M | 3.35M | 5.25M | 3.35M | 7.32M | 5.00M | 7.11M | 8.41M |
| Total Liabilities | 1.71M | 1.84M | 902K | 556K | 700K | 709K | 921K | 942K | 1.73M | 5.55M | 6.50M |
| Shareholders' Equity | 11.6M | 6.40M | 3.90M | 4.76M | 2.65M | 4.54M | 2.42M | 6.38M | 3.27M | 1.56M | 1.91M |
| Cash & Short-term Investments | 6.09M | 3.35M | 2.11M | 3.21M | 1.87M | 3.26M | 1.47M | 5.50M | 2.37M | 4.66M | 6.61M |
| Total Debt | - | - | - | 97.2K | 166K | 93.9K | 246K | 175K | 1.08M | 14.5K | 228K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -6.41M | -6.42M | -2.19M | 1.19M | -1.42M | -3.10M | -1.67M | -3.18M | -3.97M | 1.10M | -198K |
| Capital Expenditure | 62.3K | 55.6K | 424.00 | 5.15K | 5.15K | 203K | 53.1K | 5.00 | 0.00 | 0.00 | 8.00K |
| Free Cash Flow | -6.47M | -6.48M | -2.19M | 1.19M | -1.43M | -3.30M | -1.72M | -3.18M | -3.97M | 1.10M | -206K |
| Ratios | |||||||||||
| ROE | -148.7% | -134.6% | -102.3% | 17.9% | -99.3% | -75.3% | -96.6% | -53.9% | -95.5% | -283.2% | -403.4% |
| ROA | -129.7% | -104.6% | -83.1% | 16.0% | -78.5% | -65.1% | -70.0% | -47.0% | -62.5% | -62.2% | -91.5% |
| Net Profit Margin | -1,090.3% | -749.4% | -318.8% | 20.1% | -685.1% | -430.4% | -207.4% | -725.8% | -275.6% | -356.8% | -3,227.5% |
| Debt to Equity | - | - | - | 0.02x | 0.06x | 0.02x | 0.10x | 0.03x | 0.33x | 0.01x | 0.12x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Avecho Biotechnology Ltd dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- May 19, 1997
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | AUD 4.40M | 0.00 | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.27:1 on Apr 23, 1999.
Who owns Avecho Biotechnology Ltd
- Insiders 27.02%
- Institutions 0.00%
- Public & others 72.98%
- Shares outstanding 3.86B
- Free float 2.45B
Avecho Biotechnology Ltd company profile
- Company name
- Avecho Biotechnology Ltd
- Ticker
- AVE.AU
- ISIN
- AU0000047441
- Exchange
- Australian Securities Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- Hallmarc Business Park, Clayton, VIC, Australia, 3168
- Phone
- 61 3 9002 5000
- Website
- avecho.com.au
About Avecho Biotechnology Ltd
Avecho Biotechnology Limited, a biotechnology company, develops and commercializes human and animal health products using its proprietary drug delivery system, tocopherol phosphate mixture (TPM) in Australia, Switzerland, France, and India. It operates through Production and Human Health segments. The company manufactures and sells TPM and Vital ET products for use in drug delivery and cosmetic formulations. Its human health portfolio covers delivery of pharmaceutical products through gels, injectables, and patches. In addition, the company develops pharmaceutical products; oral, topical, and edible pharmaceutical cannabinoid products, including a cannabidiol TPM soft-gel capsule in Phase III clinical trial for the treatment of insomnia; and non-antibiotic feed additive products to enhance feed efficiency and the health of livestock animals. The company was formerly known as Phosphagenics Limited and changed its name to Avecho Biotechnology Limited in May 2019. Avecho Biotechnology Limited was incorporated in 1992 and is based in Clayton, Australia.
Avecho Biotechnology Ltd management
3- Dr. Paul Gavin BSc (Hons), Ph.D.Chief Executive Officer
- Dr. Roksan Libinaki Ph.D.Chief Operating Officer
- Ms. Naomi LawrieCompany Secretary